Li Li1, Chun-Yan Gou1, Xue-Mei Li2, Wen-Yan Song3, Xiao-Jun Wang1, Hong-Ying Li1, Hong-Yan Li1, Xiu-Hui Li4. 1. Integrated Traditional Chinese and Western Medicine Center, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. 2. Chronic Disease Management Center, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. 3. Department of Radiology, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. 4. Integrated Traditional Chinese and Western Medicine Center, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. lixiuhui@sohu.com.
Abstract
OBJECTIVE: To observe the changes of symptoms, Chinese medicine (CM) syndrome, and lung inflammation absorption during convalescence in patients with coronavirus disease 2019 (COVID-19) who had not totally recovered after hospital discharge and whether CM could promote the improvement process. METHODS: This study was designed as a prospective cohort and nested case-control study. A total of 96 eligible patients with COVID-19 in convalescence were enrolled from Beijing Youan Hospital and Beijing Huimin Hospital and followed up from the hospital discharged day. Patients were divided into the CM (64 cases) and the control groups (32 cases) based on the treatment with or without CM and followed up at 14, 28, 56, and 84 days after discharge. In the CM group, patients received the 28-day CM treatment according to two types of CM syndrome. Improvements in clinical symptoms, CM syndrome, and absorption of lung inflammation were observed. RESULTS: All the 96 patients completed the 84-day follow-up from January 21 to March 28, 2020. By the 84th day of follow-up, respiratory symptoms were less than 5%. There was no significant difference in the improvement rates of symptoms, including fatigue, sputum, cough, dry throat, thirst, and upset, between the two groups (P>0.05). Totally 82 patients (85.42%) showed complete lung inflammation absorption at the 84-day follow-up. On day 14, the CM group had a significantly higher absorption rate than the control group (P<0.05) and the relative risk of absorption for CM vs. control group was 3.029 (95% confidence interval: 1.026-8.940). The proportions of CM syndrome types changed with time prolonging: the proportion of the pathogen residue syndrome gradually decreased, and the proportion of both qi and yin deficiency syndrome gradually increased. CONCLUSIONS: Patients with COVID-19 in convalescence had symptoms and lung inflammation after hospital discharge and recovered with time prolonging. CM could improve lung inflammation for early recovery. The types of CM syndrome can be transformed with time prolonging. (Registration No. ChiCTR2000029430).
OBJECTIVE: To observe the changes of symptoms, Chinese medicine (CM) syndrome, and lung inflammation absorption during convalescence in patients with coronavirus disease 2019 (COVID-19) who had not totally recovered after hospital discharge and whether CM could promote the improvement process. METHODS: This study was designed as a prospective cohort and nested case-control study. A total of 96 eligible patients with COVID-19 in convalescence were enrolled from Beijing Youan Hospital and Beijing Huimin Hospital and followed up from the hospital discharged day. Patients were divided into the CM (64 cases) and the control groups (32 cases) based on the treatment with or without CM and followed up at 14, 28, 56, and 84 days after discharge. In the CM group, patients received the 28-day CM treatment according to two types of CM syndrome. Improvements in clinical symptoms, CM syndrome, and absorption of lung inflammation were observed. RESULTS: All the 96 patients completed the 84-day follow-up from January 21 to March 28, 2020. By the 84th day of follow-up, respiratory symptoms were less than 5%. There was no significant difference in the improvement rates of symptoms, including fatigue, sputum, cough, dry throat, thirst, and upset, between the two groups (P>0.05). Totally 82 patients (85.42%) showed complete lung inflammation absorption at the 84-day follow-up. On day 14, the CM group had a significantly higher absorption rate than the control group (P<0.05) and the relative risk of absorption for CM vs. control group was 3.029 (95% confidence interval: 1.026-8.940). The proportions of CM syndrome types changed with time prolonging: the proportion of the pathogen residue syndrome gradually decreased, and the proportion of both qi and yin deficiency syndrome gradually increased. CONCLUSIONS: Patients with COVID-19 in convalescence had symptoms and lung inflammation after hospital discharge and recovered with time prolonging. CM could improve lung inflammation for early recovery. The types of CM syndrome can be transformed with time prolonging. (Registration No. ChiCTR2000029430).
Entities:
Keywords:
COVID-19; Chinese medicine; convalescent patient; pneumonia absorption; syndrome evolution
Authors: Harrison X Bai; Ben Hsieh; Zeng Xiong; Kasey Halsey; Ji Whae Choi; Thi My Linh Tran; Ian Pan; Lin-Bo Shi; Dong-Cui Wang; Ji Mei; Xiao-Long Jiang; Qiu-Hua Zeng; Thomas K Egglin; Ping-Feng Hu; Saurabh Agarwal; Fang-Fang Xie; Sha Li; Terrance Healey; Michael K Atalay; Wei-Hua Liao Journal: Radiology Date: 2020-03-10 Impact factor: 11.105
Authors: Ho Yuen Frank Wong; Hiu Yin Sonia Lam; Ambrose Ho-Tung Fong; Siu Ting Leung; Thomas Wing-Yan Chin; Christine Shing Yen Lo; Macy Mei-Sze Lui; Jonan Chun Yin Lee; Keith Wan-Hang Chiu; Tom Wai-Hin Chung; Elaine Yuen Phin Lee; Eric Yuk Fai Wan; Ivan Fan Ngai Hung; Tina Poy Wing Lam; Michael D Kuo; Ming-Yen Ng Journal: Radiology Date: 2020-03-27 Impact factor: 11.105